Post-Covid-19 Epidemic Era, Rituximab Biosimilars Industry Development Trend Analysis Report 2023

Report ID: ARS12685 | Category: Healthcare and Pharmaceuticals | Pages: 128 | Format: PDF | Published Date: December 18,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3900.00 Multi User-$6800.00

Report Description
View Table of Contents

Report Summary

The global Rituximab Biosimilars market size in 2022 is 2050.0 million US dollars, and it is expected to be 5689.7 million US dollars by 2029, with a compound annual growth rate of 15.70% expected in 2023-2029.

MARKET COMPETITIVE LANDSCAPE:
The main players in the Rituximab Biosimilars market include Innovent Biologics Inc, Gedeon Richter Plc., BioXpress Therapeutics SA, Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited. The share of the top 3 players in the Rituximab Biosimilars market is XX%.

REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Rituximab Biosimilars market, and Asia Pacific accounted for XX%.

SEGMENT OVERVIEW:
The report segments the market by Type and Application. Non-Hodgkin’s Lymphoma accounted for XX% of Rituximab Biosimilars market in 2022. Chronic Lymphocytic Leukaemia share of XX%.
Hospital Based Pharmacies accounted for XX% of the Rituximab Biosimilars market in 2022. Online Pharmacies accounts for XX%.

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Rituximab Biosimilars Market dynamics, structure by identifying and analyzing the market segments and project the global market size.

In addition, the market SWOT analysis, dynamics, trends, technologies, opportunities and challenges analysis are covered in the report.

Further, the report also focuses on the competitive analysis of key players by product, financial position, product portfolio, growth strategies, and regional presence.
Chapter Outline
Chapter 1: Introduces the product overview, market scope, product classification, and application division, and then includes research purposes, report timeline, and economic analysis of global regions.
Chapter 2: Analyzes the main companies in the Rituximab Biosimilars industry, including their main businesses, products/services, revenue, gross and gross margin.
Chapters 3-5: Segmented the global Rituximab Biosimilars market by type, application and region. Analyze the revenue and sales of market segments from different perspectives.
Chapters 6-11: Provide North America, EMEA, China, Asia-Pacific and Latin America Rituximab Biosimilars market type, application, country and player market segmentation revenue data.
Chapter 12: Introduces the market dynamics, the trends factors and drivers factors of the market, and the challenges and restraints faced by manufacturers in the industry, and includes industry mergers & acquisitions and industry new entrants and expansion plans.
Chapter 13: The main points and conclusions of the report.

Highlights-Regions

North America
United States
Canada
China
Asia Pacific (Excluding China)
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Nordic
Latin America
Brazil
Argentina
Mexico
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Player list
Innovent Biologics Inc
Gedeon Richter Plc.
BioXpress Therapeutics SA
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Sandoz International GmbH (Novartis)
Zydus Lifesciences Ltd.
Hetero Drugs Limited
Dr Reddy's Laboratories Ltd
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Zenotech Laboratories
Napp Pharmaceuticals Limited
Mundipharma International Limited

Types list
Non-Hodgkin’s Lymphoma
Chronic Lymphocytic Leukaemia
Rheumatoid Arthritis
Others

Application list
Hospital Based Pharmacies
Online Pharmacies
Retail Pharmacies

Table of Content

1 Rituximab Biosimilars  Market Introduction and Overview
1.1 Rituximab Biosimilars  Definition
1.2 Market Size Analysis by Types
1.3 Market Size Analysis by Application
1.4 Research Purposes
1.5 Report Timeline
1.6 Economic Analysis of Global Regions
2 Players Profiles
2.1  Innovent Biologics Inc
2.1.1 Innovent Biologics Inc Company Profile
2.1.2 Rituximab Biosimilars  Product Overview
2.1.3 Innovent Biologics Inc Rituximab Biosimilars  Market Performance (2018-2023)
2.1.4 Innovent Biologics Inc Business Overview
2.2  Gedeon Richter Plc.
2.2.1 Gedeon Richter Plc. Company Profile
2.2.2 Rituximab Biosimilars  Product Overview
2.2.3 Gedeon Richter Plc. Rituximab Biosimilars  Market Performance (2018-2023)
2.2.4 Gedeon Richter Plc. Business Overview
2.3  BioXpress Therapeutics SA
2.3.1 BioXpress Therapeutics SA Company Profile
2.3.2 Rituximab Biosimilars  Product Overview
2.3.3 BioXpress Therapeutics SA Rituximab Biosimilars  Market Performance (2018-2023)
2.3.4 BioXpress Therapeutics SA Business Overview
2.4  Teva Pharmaceutical Industries Ltd.
2.4.1 Teva Pharmaceutical Industries Ltd. Company Profile
2.4.2 Rituximab Biosimilars  Product Overview
2.4.3 Teva Pharmaceutical Industries Ltd. Rituximab Biosimilars  Market Performance (2018-2023)
2.4.4 Teva Pharmaceutical Industries Ltd. Business Overview
2.5  Takeda Pharmaceutical Company Limited
2.5.1 Takeda Pharmaceutical Company Limited Company Profile
2.5.2 Rituximab Biosimilars  Product Overview
2.5.3 Takeda Pharmaceutical Company Limited Rituximab Biosimilars  Market Performance (2018-2023)
2.5.4 Takeda Pharmaceutical Company Limited Business Overview
2.6  Sandoz International GmbH (Novartis)
2.6.1 Sandoz International GmbH (Novartis) Company Profile
2.6.2 Rituximab Biosimilars  Product Overview
2.6.3 Sandoz International GmbH (Novartis) Rituximab Biosimilars  Market Performance (2018-2023)
2.6.4 Sandoz International GmbH (Novartis) Business Overview
2.7  Zydus Lifesciences Ltd.
2.7.1 Zydus Lifesciences Ltd. Company Profile
2.7.2 Rituximab Biosimilars  Product Overview
2.7.3 Zydus Lifesciences Ltd. Rituximab Biosimilars  Market Performance (2018-2023)
2.7.4 Zydus Lifesciences Ltd. Business Overview
2.8  Hetero Drugs Limited
2.8.1 Hetero Drugs Limited Company Profile
2.8.2 Rituximab Biosimilars  Product Overview
2.8.3 Hetero Drugs Limited Rituximab Biosimilars  Market Performance (2018-2023)
2.8.4 Hetero Drugs Limited Business Overview
2.9  Dr Reddy's Laboratories Ltd
2.9.1 Dr Reddy's Laboratories Ltd Company Profile
2.9.2 Rituximab Biosimilars  Product Overview
2.9.3 Dr Reddy's Laboratories Ltd Rituximab Biosimilars  Market Performance (2018-2023)
2.9.4 Dr Reddy's Laboratories Ltd Business Overview
2.10  Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
2.10.1 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Company Profile
2.10.2 Rituximab Biosimilars  Product Overview
2.10.3 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Rituximab Biosimilars  Market Performance (2018-2023)
2.10.4 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Business Overview
2.11  Zenotech Laboratories
2.11.1 Zenotech Laboratories Company Profile
2.11.2 Rituximab Biosimilars  Product Overview
2.11.3 Zenotech Laboratories Rituximab Biosimilars  Market Performance (2018-2023)
2.11.4 Zenotech Laboratories Business Overview
2.12  Napp Pharmaceuticals Limited
2.12.1 Napp Pharmaceuticals Limited Company Profile
2.12.2 Rituximab Biosimilars  Product Overview
2.12.3 Napp Pharmaceuticals Limited Rituximab Biosimilars  Market Performance (2018-2023)
2.12.4 Napp Pharmaceuticals Limited Business Overview
2.13  Mundipharma International Limited
2.13.1 Mundipharma International Limited Company Profile
2.13.2 Rituximab Biosimilars  Product Overview
2.13.3 Mundipharma International Limited Rituximab Biosimilars  Market Performance (2018-2023)
2.13.4 Mundipharma International Limited Business Overview
3 Global Rituximab Biosimilars  Historical and Forecast Market Analysis by Type
3.1 Global Rituximab Biosimilars  Revenue and Market Share by Type
3.2 Global Rituximab Biosimilars  Revenue Market Forecast by Type (2023-2029)
4 Global Rituximab Biosimilars  Historical and Forecast Market Analysis by Application
4.1 Global Rituximab Biosimilars  Revenue Market Share by Application (2018-2023)
4.2 Rituximab Biosimilars  Revenue Market Forecast by Application (2023-2029)
5 Global Market Growth Trends Analysis
5.1 Global Rituximab Biosimilars  Market Size & Forecast (2018-2029)
5.2 Rituximab Biosimilars  Growth Trends Analysis by Regions
5.2.1 Rituximab Biosimilars  Market Size by Regions: 2018 VS 2023 VS 2029
5.2.2 Rituximab Biosimilars  Historic Market Size by Regions (2018-2023)
5.2.3 Rituximab Biosimilars  Forecasted Market Size by Regions (2023-2029)
5.2.4 North America Rituximab Biosimilars  Market Size & Forecast (2018-2029)
5.2.5 Europe Rituximab Biosimilars  Market Size & Forecast (2018-2029)
5.2.6 China Rituximab Biosimilars  Market Size & Forecast (2018-2029)
5.2.7 Asia-Pacific (Excluding China) Rituximab Biosimilars  Market Size & Forecast (2018-2029)
5.2.8 Latin America Rituximab Biosimilars  Market Size & Forecast (2018-2029)
5.2.9 Middle East & Africa Rituximab Biosimilars  Market Size & Forecast (2018-2029)
6 North America
6.1 North America Rituximab Biosimilars  Revenue by Players
6.2 North America Rituximab Biosimilars  Revenue by Types
6.3 North America Rituximab Biosimilars  Revenue by Applications
6.4 North America Rituximab Biosimilars  Market by Countries
6.4.1 North America Rituximab Biosimilars  Revenue by Countries (2018-2029)
6.5 United States
6.6 Canada
7 China
7.1 China Rituximab Biosimilars  Revenue by Players
7.2 China Rituximab Biosimilars  Revenue by Types
7.3 China Rituximab Biosimilars  Revenue by Applications
7.4 China
8 Asia Pacific (Excluding China)
8.1 Asia Pacific Rituximab Biosimilars  Revenue by Players
8.2 Asia Pacific Rituximab Biosimilars  Revenue by Types
8.3 Asia Pacific Rituximab Biosimilars  Revenue by Applications
8.4 Asia Pacific Rituximab Biosimilars  Market by Countries
8.4.1 Asia Pacific Rituximab Biosimilars  Revenue by Countries (2018-2029)
8.5 Japan
8.6 Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Europe
9.1 Europe Rituximab Biosimilars  Revenue by Players
9.2 Europe Rituximab Biosimilars  Revenue by Types
9.3 Europe Rituximab Biosimilars  Revenue by Applications
9.4 Europe Rituximab Biosimilars  Market by Countries
9.4.1 Europe Rituximab Biosimilars  Revenue by Countries (2018-2029)
9.5 Germany
9.6 France
9.7 UK
9.8 Italy
9.9 Russia
9.10 Nordic
10 Latin America
10.1 Latin America Rituximab Biosimilars  Revenue by Players
10.2 Latin America Rituximab Biosimilars  Revenue by Types
10.3 Latin America Rituximab Biosimilars  Revenue by Applications
10.4 Latin America Rituximab Biosimilars  Market by Countries
10.4.1 Latin America Rituximab Biosimilars  Revenue by Countries (2018-2029)
10.5 Brazil
10.6 Argentina
10.7 Mexico
11 Middle East & Africa
11.1 Middle East & Africa Rituximab Biosimilars  Revenue by Players
11.2 Middle East & Africa Rituximab Biosimilars  Revenue by Types
11.3 Middle East & Africa Rituximab Biosimilars  Revenue by Applications
11.4 Middle East & Africa Rituximab Biosimilars  Market by Countries
11.4.1 Middle East & Africa Rituximab Biosimilars  Revenue by Countries (2018-2029)
11.5 Egypt
11.6 South Africa
11.7 Israel
11.8 Turkey
11.9 GCC Countries
12 Rituximab Biosimilars  Industry Dynamic Analysis
12.1 Rituximab Biosimilars  Market Trends Analysis
12.2 Rituximab Biosimilars  Market Drivers Analysis
12.3 Rituximab Biosimilars  Market Challenges Analysis
12.4 Rituximab Biosimilars  Market Restraints Analysis
12.5 Rituximab Biosimilars  Industry Mergers & Acquisitions
12.6 Rituximab Biosimilars  Industry New Entrants and Expansion Plans
13 Research Findings and Conclusion

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Post-Covid-19 Epidemic Era, Rituximab Biosimilars Industry Development Trend Analysis Report 2023

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?